Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study
Infection Control & Hospital Epidemiology · 2025
DOI: 10.1017/ice.2025.35 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Infection Control & Hospital Epidemiology, 2025. Verfasst von Dan Ilges und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Mayo Clinic Arizona, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Procalcitonin, Community-Acquired Infections, Anti-Bacterial Agents, Pneumonia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objective
To retrospectively observe procalcitonin (PCT) and antibiotic ordering practices in patients hospitalized with community-acquired pneumonia (CAP).
Design
Retrospective, exact matched, multicenter cohort study from October 1, 2018 – March 31, 2023.
Setting
All hospitals across the Mayo Clinic Enterprise.
Participants
Adult patients with CAP, identified using pneumonia diagnosis codes and receipt of systemic antibiotics with an indication of “respiratory tract infection” within 48 hours of hospitalization.
Methods
PCT testing within the first 7 days of hospitalization was compared to non-PCT care (nPCT). The primary outcomes were treatment duration, antibiotic days of therapy (DOT), and length of stay (LOS).
Results
15364 patients met inclusion criteria. PCT testing occurred in 42.4% (6515/15364) of encounters, totaling 8214 PCT results. 12880 unique patient encounters were matched 1:1, 6440 in each group. Treatment duration was longer in the PCT group compared to the nPCT group (5.1 vs 4.6 days, respectively, P < 0.001). Patients in the PCT group also received more DOT (8.6 vs 7.6 DOT, P < 0.001) and had a longer LOS (6.8 vs 5.9 days, P < 0.001), respectively. There was no difference in 30-day all-cause mortality or C. difficile infection between groups. In a sensitivity analysis of nPCT patients compared to those with a peak value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Mayo Clinic Arizona, Phoenix, AZ, USA.
- Department of Pharmacy Services, Mayo Clinic, Rochester, MN, USA.
- Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, USA.
- Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Dan Ilges, Dylan Kosaski, Maria Teresa Seville, Alyssa K McGary, John C O'Horo, Christine L Snozek, Ryan W Stevens
Zitieren
APA
Ilges, D., Kosaski, D., Seville, M. T., McGary, A. K., O'Horo, J. C., Snozek, C. L., Stevens, R. W., & Shah, A. (2025). Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2025.35
Vancouver
Ilges D, Kosaski D, Seville MT, McGary AK, O'Horo JC, Snozek CL, et al. Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study. Infection Control & Hospital Epidemiology. 2025. doi:10.1017/ice.2025.35
BibTeX
@article{Ilges2025,
author = {Ilges, Dan and Kosaski, Dylan and Seville, Maria Teresa and McGary, Alyssa K and O'Horo, John C and Snozek, Christine L and Stevens, Ryan W and Shah, Aditya},
title = {Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study},
journal = {Infection Control & Hospital Epidemiology},
year = {2025},
doi = {10.1017/ice.2025.35}
}
EUVIMED